Hasil Pencarian - Timothy P Hughes

Perbaiki Hasil
  1. 1
    ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines.

    ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines. oleh Laura N Eadie, Timothy P Hughes, Deborah L White

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

    Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers oleh Vaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P. Hughes, Susan Branford, S. Tiong Ong

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells.

    ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. oleh Laura N Eadie, Phuong Dang, Jarrad M Goyne, Timothy P Hughes, Deborah L White

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

    Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells oleh Devendra K. Hiwase, Verity A. Saunders, Eva Nievergall, Douglas D. Ross, Deborah L. White, Timothy P. Hughes

    Diterbitkan 2013-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism

    The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism oleh Benjamin C. S. Leow, Chung H. Kok, David T. Yeung, Timothy P. Hughes, Deborah L. White, Laura N. Eadie

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells

    Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells oleh Marc García-Montolio, Cecilia Ballaré, Enrique Blanco, Arantxa Gutiérrez, Sergi Aranda, Antonio Gómez, Chung H. Kok, Chung H. Kok, David T. Yeung, David T. Yeung, Timothy P. Hughes, Timothy P. Hughes, Pedro Vizán, Luciano Di Croce, Luciano Di Croce, Luciano Di Croce

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib

    Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib oleh Chung H. Kok, Verity A. Saunders, Phuong Dang, Naranie Shanmuganathan, Deborah White, Susan Branford, David Yeung, Timothy P. Hughes

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    OCT-1 function varies with cell lineage but is not influenced by BCR-ABL

    OCT-1 function varies with cell lineage but is not influenced by BCR-ABL oleh Jane R. Engler, Andrew C.W. Zannettino, Charles G. Bailey, John E.J. Rasko, Timothy P. Hughes, Deborah L. White

    Diterbitkan 2011-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

    Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial oleh François Guilhot, Timothy P. Hughes, Jorge Cortes, Brian J. Druker, Michele Baccarani, Insa Gathmann, Michael Hayes, Camille Granvil, Yanfeng Wang

    Diterbitkan 2012-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells

    Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells oleh Jueqiong Wang, Liu Lu, Chung H. Kok, Verity A. Saunders, Jarrad M. Goyne, Phuong Dang, Tamara M. Leclercq, Timothy P. Hughes, Deborah L. White

    Diterbitkan 2017-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

    Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia oleh Timothy P. Hughes, Pierre Laneuville, Philippe Rousselot, David S. Snyder, Delphine Rea, Neil P. Shah, David Paar, Elisabetta Abruzzese, Andreas Hochhaus, Jeffrey H. Lipton, Jorge E. Cortes

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

    Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation oleh Shady Adnan Awad, Oscar Brück, Naranie Shanmuganathan, Timo Jarvinen, Hanna Lähteenmäki, Jay Klievink, Hazem Ibrahim, Soili Kytölä, Perttu Koskenvesa, Timothy P. Hughes, Susan Branford, Matti Kankainen, Satu Mustjoki

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Chronic myeloid leukemia: reminiscences and dreams

    Chronic myeloid leukemia: reminiscences and dreams oleh Tariq I. Mughal, Jerald P. Radich, Michael W. Deininger, Jane F. Apperley, Timothy P. Hughes, Christine J. Harrison, Carlo Gambacorti-Passerini, Giuseppe Saglio, Jorge Cortes, George Q. Daley

    Diterbitkan 2016-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

    BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia oleh Ilaria S. Pagani, Phuong Dang, Ivar O. Kommers, Jarrad M. Goyne, Mario Nicola, Verity A. Saunders, Jodi Braley, Deborah L. White, David T. Yeung, Susan Branford, Timothy P. Hughes, David M. Ross

    Diterbitkan 2018-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure

    ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure oleh Justine E. Marum, David T. Yeung, Leanne Purins, John Reynolds, Wendy T. Parker, Doris Stangl, Paul P.S. Wang, David J. Price, Jonathan Tuke, Andreas W. Schreiber, Hamish S. Scott, Timothy P. Hughes, Susan Branford

    Diterbitkan 2017-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

    Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imati... oleh Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian, Francisco Cervantes, François Guilhot, Dietger Niederwieser, Philipp D. le Coutre, Gianantonio Rosti, Gert Ossenkoppele, Clarisse Lobo, Hirohiko Shibayama, Xiaolin Fan, Hans D. Menssen, Charisse Kemp, Richard A. Larson, Giuseppe Saglio

    Diterbitkan 2014-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

    Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized... oleh Deborah L. White, Jerald Radich, Simona Soverini, Verity A Saunders, Amity K. Frede, Phuong Dang, Daniela Cilloni, Peter Lin, Lidia Mongay, Richard Woodman, Paul Manley, Cassandra Slader, Dong Wook Kim, Fabrizio Pane, Giovanni Martinelli, Giuseppe Saglio, Timothy P. Hughes

    Diterbitkan 2012-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.

    Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. oleh Daniel Thomas, Jason A Powell, Benjamin D Green, Emma F Barry, Yuefang Ma, Joanna Woodcock, Stephen Fitter, Andrew C W Zannettino, Stuart M Pitson, Timothy P Hughes, Angel F Lopez, Peter R Shepherd, Andrew H Wei, Paul G Ekert, Mark A Guthridge

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

    Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy oleh Sabrina Angelini, Simona Soverini, Gloria Ravegnini, Matt Barnett, Eleonora Turrini, Mark Thornquist, Fabrizio Pane, Timothy P. Hughes, Deborah L. White, Jerald Radich, Dong Wook Kim, Giuseppe Saglio, Daniela Cilloni, Ilaria Iacobucci, Giovanni Perini, Richard Woodman, Giorgio Cantelli-Forti, Michele Baccarani, Patrizia Hrelia, Giovanni Martinelli

    Diterbitkan 2013-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    A dual role for the N-terminal domain of the IL-3 receptor in cell signalling

    A dual role for the N-terminal domain of the IL-3 receptor in cell signalling oleh Sophie E. Broughton, Timothy R. Hercus, Tracy L. Nero, Winnie L. Kan, Emma F. Barry, Mara Dottore, Karen S. Cheung Tung Shing, Craig J. Morton, Urmi Dhagat, Matthew P. Hardy, Nicholas J. Wilson, Matthew T. Downton, Christine Schieber, Timothy P. Hughes, Angel F. Lopez, Michael W. Parker

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: